Classical Hodgkin's lymphoma accounts for approximately 10% of all malignant lymphomas. Although most patients can be cured with modern treatment strategies, approximately 25% of them experience either primary or secondary chemorefractoriness or disease relapse, thus requiring novel treatments. Increasing preclinical and clinical evidences have demonstrated the role of microenvironment in the molecular pathogenesis of classical Hodgkin's lymphoma and elucidated the complex cross-talk between the malignant Hodgkin Reed-Sternberg cells and the nonmalignant, reactive cells of the microenvironment, strongly supporting novel therapeutic approaches aimed at targeting Hodgkin's Reed-Sternberg cells along with reactive cells in order to overcome chemorefractoriness. In the near future, these novel therapies will also be tested in chemosensitive patients to reduce long-term toxicities of chemo-radiotherapy.
|Titolo:||Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma|
CARLO STELLA, CARMELO (Primo)
|Parole Chiave:||CD30; Hodgkin Reed–Sternberg cells; PD-1 ligands; PD-1 receptor; brentuximab vedotin; classical Hodgkin's lymphoma; nivolumab; relapsed/refractory Hodgkin's lymphoma; targeted therapy; tumor microenvironment|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||ago-2015|
|Digital Object Identifier (DOI):||10.2217/BMM.15.30|
|Appare nelle tipologie:||01 - Articolo su periodico|